Cambridge Cancer Genomics
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Cambridge Cancer Genomics (CCG) was a UK-based cancer informatics company founded in 2017. It built OncOS, an artificial-intelligence-based precision oncology software platform that combined medical, germline, somatic and liquid biopsy data to support patient-centric precision oncology at scale. The company also partnered with Dante Labs and Nonacus to build a high-throughput cancer sequencing and interpretation service for tumor profiling.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Founded
Founded in the United Kingdom to apply machine learning and genomics data analysis to precision oncology.
- Tumor profiling partnership
Began working with Dante Labs and Nonacus on a high-throughput cancer sequencing and interpretation service for tumor profiling.
- Acquired by Dante Labs
Acquired by Dante Labs, a New York-based genomics company, for an undisclosed amount. CCG's OncOS software was to be integrated into Dante Labs' Immensa Genomics Interpretation Software for clinical and research customers.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.